Regions :: North America :: U.S.
AMRI to acquire OsoBio for $110 million
12:10 PM MDT | June 2, 2014 | Deepti Ramesh
Albany Molecular Research Inc. (AMRI; Albany, NY) says that it has signed a definitive agreement to acquire Oso Biopharmaceuticals Manufacturing (OsoBio; Albuquerque, NM) for $110 million in cash. OsoBio is contract manufacturer of highly complex, injectable drug products, including sterile liquid, suspension, and lyophilized formulations. The acquisition is expected to be completed in the third quarter. OsoBio's forecast full-year 2014 revenue is $58–60 million, with adjusted Ebitda of $9–10 million, AMRI says. “The acquisition of OsoBio is...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee